PGNX - Progenics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5454.33M
Enterprise Value 3393.94M
Trailing P/E N/A
Forward P/E 1-87.67
PEG Ratio (5 yr expected) 1-0.03
Price/Sales (ttm)27.18
Price/Book (mrq)5.33
Enterprise Value/Revenue 323.57
Enterprise Value/EBITDA 6-7.45

Trading Information

Stock Price History

Beta (3Y Monthly) 2.60
52-Week Change 3-32.91%
S&P500 52-Week Change 36.70%
52 Week High 39.42
52 Week Low 33.62
50-Day Moving Average 35.08
200-Day Moving Average 34.77

Share Statistics

Avg Vol (3 month) 3802.55k
Avg Vol (10 day) 3686.47k
Shares Outstanding 584.74M
Float 71.91M
% Held by Insiders 16.46%
% Held by Institutions 186.34%
Shares Short (Jun 28, 2019) 410.11M
Short Ratio (Jun 28, 2019) 411.98
Short % of Float (Jun 28, 2019) 414.28%
Short % of Shares Outstanding (Jun 28, 2019) 411.70%
Shares Short (prior month May 31, 2019) 49.78M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019


Profit Margin 0.00%
Operating Margin (ttm)-327.11%

Management Effectiveness

Return on Assets (ttm)-22.42%
Return on Equity (ttm)-101.35%

Income Statement

Revenue (ttm)16.71M
Revenue Per Share (ttm)0.21
Quarterly Revenue Growth (yoy)34.20%
Gross Profit (ttm)15.62M
EBITDA -52.91M
Net Income Avi to Common (ttm)-72.97M
Diluted EPS (ttm)-0.90
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)109.59M
Total Cash Per Share (mrq)1.3
Total Debt (mrq)58.83M
Total Debt/Equity (mrq)70.56
Current Ratio (mrq)4.81
Book Value Per Share (mrq)0.99

Cash Flow Statement

Operating Cash Flow (ttm)-51.02M
Levered Free Cash Flow (ttm)-30.7M